Macrophage and IL-6 signaling modulate multiple myeloma progression and response to metformin and CAR-T cell therapy

Xuanyou Liu, Iris Kemler, David Dingli · 2026

Read Macrophage and IL-6 signaling modulate multiple myeloma progression and response to metformin and CAR-T cell therapy by Xuanyou Liu, Iris Kemler, David Dingli (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13128645.txt.

Description

Xuanyou Liu, Iris Kemler, and David Dingli study how immune bystander cells shape a blood cancer's response to therapy in a 2026 paper. Multiple myeloma cells carry a receptor for a signal called IL-6, and engineered T cells targeting that receptor can kill them. But macrophages in the tumor neighborhood also steer the signal, for better or worse.

In lab cultures, inflammatory style macrophages shrank the myeloma population and raised cell death. The diabetes drug metformin lowered the cells' survival and reduced their receptor levels. Yet culturing with macrophages also weakened the engineered T cells' killing, likely through direct tangles between the two immune cell types. The authors say optimizing cell therapy must reckon with macrophages.

Catalog record

CREATORXuanyou Liu, Iris Kemler, David Dingli
YEAR2026
COLLECTIONPAPERS
FORMATTXT
FILE SIZE45 KB
VERSION1.0
LICENSECC BY 4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/articles/PMC13128645

Browse the full library · About the Tower of Babel